MitoSense

MitoSense Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. Their core technology, Mitochondria Organelle Transplantation (MOT), aims to replenish damaged mitochondria in patients, initially targeting Amyotrophic Lateral Sclerosis (ALS). This approach has the potential to treat various neurodegenerative conditions.

Funding Round: Seed

Funding Amount: $3.5M

Date: 22-Jan-2024

Investors: Caydan Capital Partners

Markets: Biotechnology, Healthtech, Neurodegenerative Diseases, Drug Discovery, Life Sciences

HQ: Great Falls, VA, United States

Founded: 2019

Website: https://www.mitosenseinc.com/

LinkedIn: https://www.linkedin.com/company/mitosense

Twitter: https://twitter.com/MitoSenseInc

Instagram:

Facebook: https://www.facebook.com/mitosense